N-(Piperidin-4-yl)methanesulfonamide → N-[1-(4-{5-[1-(2-fluorophenyl)-5-pyridin-4-yl-1H-1,2,3-triazol-4-yl]-1,2,4-oxadiazol-3-yl}benzyl)piperidin-4-yl]methanesulfonamide

Participants

Reaction Steps

The title compound was prepared following the procedure described for Example 94, but starting from 4-(5-(1-(2-fluorophenyl)-5-(pyridin-4-yl)-1H-1,2,3-triazol-4-yl)-1,2,4-oxadiazol-3-yl)benzaldehyde, obtained as described in Example 113, Step 1, (100 mg; 0.24 mmol) and N-(piperidin-4-yl)methanesulfonamide (86.5 mg; 0.48 mmol) to give Example 146 as a white solid. 1H NMR: (CDCl3, 400 MHz) δ 8.72 (2H, dd, J=4.5, 1.6 Hz), 8.04 (2H, d, J=8.1 Hz), 7.63-7.52 (2H, m), 7.44-7.33 (5H, m), 7.22-7.15 (1H, m), 4.20 (1H, d, J=7.7 Hz), 3.55 (2H, s), 3.40-3.31 (1H, m), 2.98 (3H, s), 2.82 (2H, d, J=11.4 Hz), 2.16 (2H, t, J=11.3 Hz), 1.99 (2H, d, J=12.5 Hz), 1.66-1.50 (2H, m). LC/MS (Method C): 573 (M+H)+. HPLC (Method F) Rt 3.33 min (Purity: 99.2%).

Provenance & Evidence